Immunic (NASDAQ:IMUX) Raised to Strong-Buy at EF Hutton Acquisition Co. I

Immunic (NASDAQ:IMUX) was upgraded by research analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a note issued to investors on Monday, Zacks.com reports.

A number of other research firms have also issued reports on IMUX. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. B. Riley assumed coverage on Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 target price for the company. StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Leerink Partners reissued an “outperform” rating and set a $5.00 price target on shares of Immunic in a research report on Monday, September 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $28.00 price objective on shares of Immunic in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Immunic has a consensus rating of “Buy” and an average price target of $11.20.

Immunic Stock Up 5.3 %

Shares of IMUX opened at $1.60 on Monday. Immunic has a 52-week low of $0.95 and a 52-week high of $1.92. The stock has a market cap of $144.13 million, a PE ratio of -0.87 and a beta of 1.82. The firm’s fifty day moving average is $1.41 and its two-hundred day moving average is $1.31.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same quarter last year, the business earned ($0.54) EPS. As a group, research analysts anticipate that Immunic will post -0.92 earnings per share for the current year.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Immunic in the first quarter valued at about $25,000. Sierra Summit Advisors LLC acquired a new position in shares of Immunic in the 4th quarter worth approximately $487,000. Ikarian Capital LLC lifted its holdings in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in Immunic in the first quarter valued at approximately $9,266,000. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.